Advertisement

Course and Duration of Therapy with Parkinsonian Drugs and Withdrawal Syndromes

  • Koji AoyamaEmail author
Living reference work entry
First Online:
  • 165 Downloads

Abstract

Current strategies for the treatment of Parkinson’s disease (PD) are still mainly based on the use of dopaminergic medications such as l-dihydroxyphenylalanine (l-DOPA) and dopamine agonists to stimulate striatal dopamine receptors. Indeed, therapeutic intervention with these drugs has improved the prognosis of patients with PD over the last 50 years. However, it is still inconclusive as to which medication is the best for the initial treatment of PD and whether these medications have disease-modifying effects in the long clinical course of PD. In addition, long-term treatment with these drugs can cause complications that induce motor and non-motor symptoms, including withdrawal syndrome, in patients with PD. These symptoms are refractory to l-DOPA therapy and dominate the late-stage disability, which features some clinical milestones to the end of the disease. It is important to consider the influences of parkinsonian drug treatments on the clinical course of PD. In this chapter, therapy with parkinsonian drugs and their pharmacological properties, including adverse effects and influence on disease progression, will be discussed in detail.

This is a preview of subscription content, log in to check access.

References

  1. Abrams WB, Coutinho CB, Leon AS, Spiegel HE. Absorption and metabolism of levodopa. JAMA. 1971;218:1912–4. https://www.ncbi.nlm.nih.gov/pubmed/5171067CrossRefGoogle Scholar
  2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58. https://www.ncbi.nlm.nih.gov/pubmed/11391738CrossRefGoogle Scholar
  3. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12:366–75. https://www.ncbi.nlm.nih.gov/pubmed/2479133CrossRefGoogle Scholar
  4. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–9.  https://doi.org/10.1016/S1474-4422(07)70218-1.CrossRefPubMedGoogle Scholar
  5. Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2013;84:674–80.  https://doi.org/10.1136/jnnp-2012-303135.CrossRefPubMedGoogle Scholar
  6. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2:577–88.  https://doi.org/10.1038/35086062.CrossRefPubMedGoogle Scholar
  7. Binda C, Wang J, Pisani L, Caccia C, Carotti A, Salvati P, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007;50:5848–52.  https://doi.org/10.1021/jm070677y.CrossRefPubMedGoogle Scholar
  8. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA. 1999;96:12079–84. https://www.ncbi.nlm.nih.gov/pubmed/10518579CrossRefGoogle Scholar
  9. Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH, Chirilineau D, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29:1273–80.  https://doi.org/10.1002/mds.25961.CrossRefPubMedGoogle Scholar
  10. Braak H, Del Tredici K. Invited article: Nervous system pathology in sporadic Parkinson disease. Neurology. 2008;70:1916–25.  https://doi.org/10.1212/01.wnl.0000312279.49272.9f.CrossRefPubMedGoogle Scholar
  11. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211. http://www.ncbi.nlm.nih.gov/pubmed/12498954CrossRefGoogle Scholar
  12. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18:733–46. https://www.ncbi.nlm.nih.gov/pubmed/15330687CrossRefGoogle Scholar
  13. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol. 2008;75:63–75.  https://doi.org/10.1016/j.bcp.2007.06.043.CrossRefPubMedGoogle Scholar
  14. Brown JH, Laiken N. Muscarinic agonists and antagonists. In: Brunton LL, editor. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw Hill Medical; 2011. p. 219–37.Google Scholar
  15. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67:S18–23.  https://doi.org/10.1212/wnl.67.7_suppl_2.s18.CrossRefPubMedGoogle Scholar
  16. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson’s disease. Neurobiol Dis. 2003;14:404–16. https://www.ncbi.nlm.nih.gov/pubmed/14678757CrossRefGoogle Scholar
  17. Cattaneo C, Sardina M, Bonizzoni E. Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease fluctuating patients: post hoc analyses of studies 016 and SETTLE. J Park Dis. 2016;6:165–73.  https://doi.org/10.3233/JPD-150700.CrossRefGoogle Scholar
  18. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75:494–9.  https://doi.org/10.1212/WNL.0b013e3181ec7fac.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670–83.  https://doi.org/10.1001/jama.2014.3654.CrossRefPubMedGoogle Scholar
  20. Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol. 2010;257:S253–61.  https://doi.org/10.1007/s00415-010-5728-8.CrossRefPubMedGoogle Scholar
  21. Da Prada M, Kettler R, Zurcher G, Schaffner R, Haefely WE. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. Eur Neurol. 1987;27(Suppl 1):9–20. http://www.ncbi.nlm.nih.gov/pubmed/3123242CrossRefGoogle Scholar
  22. Dairman W, Udenfriend S. Decrease in adrenal tyrosine hydroxylase and increase in norepinephrine synthesis in rats given l-dopa. Science. 1971;171:1022–4. https://www.ncbi.nlm.nih.gov/pubmed/5542806CrossRefGoogle Scholar
  23. Dairman W, Christenson JG, Udenfriend S. Decrease in liver aromatic l-amino-acid decarboxylase produced by chronic administration of l-dopa. Proc Natl Acad Sci USA. 1971;68:2117–20. https://www.ncbi.nlm.nih.gov/pubmed/5289371CrossRefGoogle Scholar
  24. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001;49:298–303. https://www.ncbi.nlm.nih.gov/pubmed/11261503
  25. De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 2017;74:970–6.  https://doi.org/10.1001/jamaneurol.2017.1125.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413–26. https://www.ncbi.nlm.nih.gov/pubmed/12030260CrossRefGoogle Scholar
  27. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013;62:132–44.  https://doi.org/10.1016/j.freeradbiomed.2013.01.018.CrossRefPubMedGoogle Scholar
  28. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38:1237–44. https://www.ncbi.nlm.nih.gov/pubmed/3399075CrossRefGoogle Scholar
  29. El Atifi-Borel M, Buggia-Prevot V, Platet N, Benabid AL, Berger F, Sgambato-Faure V. De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. Neurobiol Dis. 2009;34:340–50.  https://doi.org/10.1016/j.nbd.2009.02.002.CrossRefPubMedGoogle Scholar
  30. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol. 1987;21:370–6.  https://doi.org/10.1002/ana.410210409.CrossRefPubMedGoogle Scholar
  31. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22:1379–89; quiz 523.  https://doi.org/10.1002/mds.21475.CrossRefPubMedGoogle Scholar
  32. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.  https://doi.org/10.1056/NEJMoa033447.CrossRefPubMedGoogle Scholar
  33. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283–301. https://www.ncbi.nlm.nih.gov/pubmed/1933245CrossRefGoogle Scholar
  34. Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, et al. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–65.  https://doi.org/10.1016/S1474-4422(15)00336-1.CrossRefPubMedGoogle Scholar
  35. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003;304:498–506.  https://doi.org/10.1124/jpet.102.042846.CrossRefPubMedGoogle Scholar
  36. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.  https://doi.org/10.1111/j.1532-5415.2011.03491.x.CrossRefPubMedGoogle Scholar
  37. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology. 1987;37:940–4. https://www.ncbi.nlm.nih.gov/pubmed/3587644CrossRefGoogle Scholar
  38. Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990;250:1429–32. https://www.ncbi.nlm.nih.gov/pubmed/2147780CrossRefGoogle Scholar
  39. Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature. 1977;265:80–1. https://www.ncbi.nlm.nih.gov/pubmed/834248CrossRefGoogle Scholar
  40. Godwin-Austen RB, Tomlinson EB, Frears CC, Kok HW. Effects of l-dopa in Parkinson’s disease. Lancet. 1969;2:165–8. https://www.ncbi.nlm.nih.gov/pubmed/4183130CrossRefGoogle Scholar
  41. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27:135–206. https://www.ncbi.nlm.nih.gov/pubmed/1103160
  42. Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 1999;20:60–80.  https://doi.org/10.1016/S0893-133X(98)00066-9.CrossRefPubMedGoogle Scholar
  43. Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson’s disease. Brain. 2014;137:2493–508.  https://doi.org/10.1093/brain/awu193.CrossRefPubMedGoogle Scholar
  44. Harada T, Mitsuoka K, Kumagai R, Murata Y, Kaseda Y, Kamei H, et al. Clinical features of malignant syndrome in Parkinson’s disease and related neurological disorders. Parkinsonism Relat Disord. 2003;9(Suppl 1):S15–23. https://www.ncbi.nlm.nih.gov/pubmed/12735911CrossRefGoogle Scholar
  45. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson’s disease. Mov Disord. 2000;15:485–9. https://www.ncbi.nlm.nih.gov/pubmed/10830413CrossRefGoogle Scholar
  46. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22:2409–17.  https://doi.org/10.1002/mds.21743.CrossRefPubMedGoogle Scholar
  47. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23:837–44.  https://doi.org/10.1002/mds.21956.CrossRefPubMedGoogle Scholar
  48. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality, Neurology. 1967; 17:427–42. https://www.ncbi.nlm.nih.gov/pubmed/6067254
  49. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–53.  https://doi.org/10.1001/archneur.61.7.1044.CrossRefPubMedGoogle Scholar
  50. Horowski R, Loschmann PA. Classical dopamine agonists. J Neural Transm (Vienna). 2019;126:449–54.  https://doi.org/10.1007/s00702-019-01989-y.CrossRefGoogle Scholar
  51. Humpel M, Krause W, Hoyer GA, Wendt H, Pommerenke G. The pharmacokinetics and biotransformation of 14C-lisuride hydrogen maleate in rhesus monkey and in man. Eur J Drug Metab Pharmacokinet. 1984;9:347–57.  https://doi.org/10.1007/BF03189685.CrossRefPubMedGoogle Scholar
  52. Ikebe S, Harada T, Hashimoto T, Kanazawa I, Kuno S, Mizuno Y, et al. Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003;9(Suppl 1):S47–9. https://www.ncbi.nlm.nih.gov/pubmed/12735915CrossRefGoogle Scholar
  53. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations. Neurology. 1996;47:785–8. https://www.ncbi.nlm.nih.gov/pubmed/8797480CrossRefGoogle Scholar
  54. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58:1611–5. https://www.ncbi.nlm.nih.gov/pubmed/11594919CrossRefGoogle Scholar
  55. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64:676–82.  https://doi.org/10.1001/archneur.64.5.676.CrossRefPubMedGoogle Scholar
  56. Jellinger KA. Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. J Neural Transm (Vienna). 2019;126:933–95.  https://doi.org/10.1007/s00702-019-02028-6.CrossRefGoogle Scholar
  57. Jiang H, Huang J, Shen Y, Guo S, Wang L, Han C, et al. RBD and neurodegenerative diseases. Mol Neurobiol. 2017;54:2997–3006.  https://doi.org/10.1007/s12035-016-9831-4.CrossRefPubMedGoogle Scholar
  58. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003; CD003735.  https://doi.org/10.1002/14651858.CD003735.
  59. Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17:749–59.  https://doi.org/10.1016/S1474-4422(18)30239-4.CrossRefPubMedGoogle Scholar
  60. Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133:1755–62.  https://doi.org/10.1093/brain/awq059.CrossRefPubMedGoogle Scholar
  61. Kipps CM, Fung VS, Grattan-Smith P, de Moore GM, Morris JG. Movement disorder emergencies. Mov Disord. 2005;20:322–34.  https://doi.org/10.1002/mds.20325.CrossRefPubMedGoogle Scholar
  62. Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol. 1989; 166:589–90.  https://doi.org/10.1016/0014-2999(89)90384-1.CrossRefPubMedGoogle Scholar
  63. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206:297–300.  https://doi.org/10.1016/0922-4106(91)90113-v.CrossRefPubMedGoogle Scholar
  64. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997;48:81–7. https://www.ncbi.nlm.nih.gov/pubmed/9008498CrossRefGoogle Scholar
  65. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28:1065–78.  https://doi.org/10.1016/j.clinthera.2006.08.004.CrossRefPubMedGoogle Scholar
  66. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001;57:1687–94. https://www.ncbi.nlm.nih.gov/pubmed/11706112CrossRefGoogle Scholar
  67. Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017;74:197–206.  https://doi.org/10.1001/jamaneurol.2016.4703.CrossRefPubMedGoogle Scholar
  68. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979;29:1253–60. https://www.ncbi.nlm.nih.gov/pubmed/573405CrossRefGoogle Scholar
  69. LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68:1262–7.  https://doi.org/10.1212/01.wnl.0000259516.61938.bb.CrossRefPubMedGoogle Scholar
  70. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.  https://doi.org/10.1212/01.wnl.0000256715.13907.d3.CrossRefPubMedGoogle Scholar
  71. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, et al. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 1985;313:656–9.  https://doi.org/10.1056/NEJM198509123131103.CrossRefPubMedGoogle Scholar
  72. Maier Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm Suppl. 1983;19:253–64. https://www.ncbi.nlm.nih.gov/pubmed/6583311
  73. Morgan JP, Bianchine JR, Spiegel HE, Rivera-Calimlim L, Hersey RM. Metabolism of levodopa in patients with Parkinson’s disease. Radioactive and fluorometric assays. Arch Neurol. 1971;25:39–44. https://www.ncbi.nlm.nih.gov/pubmed/5146410CrossRefGoogle Scholar
  74. Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003;18:738–50.  https://doi.org/10.1002/mds.10473.CrossRefGoogle Scholar
  75. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Selegiline as initial treatment in de novo parkinsonian patients. Neurology. 1992;42:339–43. https://www.ncbi.nlm.nih.gov/pubmed/1736162CrossRefGoogle Scholar
  76. Nagatsu T, Levitt M, Udenfriend S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J Biol Chem. 1964;239:2910–7. https://www.ncbi.nlm.nih.gov/pubmed/14216443
  77. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44:913–9. https://www.ncbi.nlm.nih.gov/pubmed/8190296CrossRefGoogle Scholar
  78. Nutt JG, Carter JH, Van Houten L, Woodward WR. Short- and long-duration responses to levodopa during the first year of levodopa therapy. Ann Neurol. 1997;42:349–55.  https://doi.org/10.1002/ana.410420311.CrossRefPubMedGoogle Scholar
  79. Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord. 2006;21:343–53.  https://doi.org/10.1002/mds.20724.CrossRefPubMedGoogle Scholar
  80. Olanow CW, Myllyla VV, Sotaniemi KA, Larsen JP, Palhagen S, Przuntek H, et al. Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology. 1998;51:825–30.  https://doi.org/10.1212/wnl.51.3.825.CrossRefPubMedGoogle Scholar
  81. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361:1268–78.  https://doi.org/10.1056/NEJMoa0809335.CrossRefPubMedGoogle Scholar
  82. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13:141–9.  https://doi.org/10.1016/S1474-4422(13)70293-X.CrossRefPubMedGoogle Scholar
  83. Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, et al. Amantadine extended release for levodopa-induced dyskinesia in Parkinson’s disease (EASED Study). Mov Disord. 2015;30:788–95.  https://doi.org/10.1002/mds.26159.CrossRefPubMedPubMedCentralGoogle Scholar
  84. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006;66:1200–6.  https://doi.org/10.1212/01.wnl.0000204007.46190.54.CrossRefPubMedGoogle Scholar
  85. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.  https://doi.org/10.1056/NEJM199301213280305.CrossRefGoogle Scholar
  86. PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384:1196–205.  https://doi.org/10.1016/S0140-6736(14)60683-8.CrossRefGoogle Scholar
  87. Pessoa RR, Moro A, Munhoz RP, Teive HAG, Lees AJ. Apomorphine in the treatment of Parkinson’s disease: a review. Arq Neuropsiquiatr. 2018;76:840–8.  https://doi.org/10.1590/0004-282X20180140.CrossRefPubMedGoogle Scholar
  88. Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Neurology. 1996;47:S146–52. https://www.ncbi.nlm.nih.gov/pubmed/8959983CrossRefGoogle Scholar
  89. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M, Celomen Study Group. Efficacy and safety of entacapone in Parkinson’s disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002;105:245–55. https://www.ncbi.nlm.nih.gov/pubmed/11939936CrossRefGoogle Scholar
  90. Quack G, Hesselink M, Danysz W, Spanagel R. Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover. J Neural Transm Suppl. 1995;46:97–105. https://www.ncbi.nlm.nih.gov/pubmed/8821045
  91. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010;67:58–63.  https://doi.org/10.1001/archneurol.2009.294.CrossRefPubMedGoogle Scholar
  92. Rangel-Barajas C, Coronel I, Floran B. Dopamine receptors and neurodegeneration. Aging Dis. 2015;6:349–68.  https://doi.org/10.14336/AD.2015.0330.CrossRefPubMedPubMedCentralGoogle Scholar
  93. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–91.  https://doi.org/10.1056/NEJM200005183422004.CrossRefPubMedGoogle Scholar
  94. Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, et al. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016;31:1489–96.  https://doi.org/10.1002/mds.26724.CrossRefPubMedGoogle Scholar
  95. Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm. 1978;43:271–7. https://www.ncbi.nlm.nih.gov/pubmed/745019CrossRefGoogle Scholar
  96. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem. 1986;46:1359–65.  https://doi.org/10.1111/j.1471-4159.1986.tb01747.x.CrossRefPubMedGoogle Scholar
  97. Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, et al. alpha-Synuclein in Parkinson’s disease: causal or bystander? J Neural Transm (Vienna). 2019;126:815–40.  https://doi.org/10.1007/s00702-019-02025-9.CrossRefGoogle Scholar
  98. Rinne UK, Molsa P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979;29:1584–9. https://www.ncbi.nlm.nih.gov/pubmed/574221CrossRefGoogle Scholar
  99. Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, et al. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016.  https://doi.org/10.1111/ene.13034.CrossRefGoogle Scholar
  100. Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76:763–75.  https://doi.org/10.1111/bcp.12081.CrossRefPubMedPubMedCentralGoogle Scholar
  101. Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63:167–73.  https://doi.org/10.1002/ana.21291.CrossRefPubMedGoogle Scholar
  102. Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013;12:747–55.  https://doi.org/10.1016/S1474-4422(13)70117-0.CrossRefPubMedPubMedCentralGoogle Scholar
  103. Scheller D, Ullmer C, Berkels R, Gwarek M, Lubbert H. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379:73–86.  https://doi.org/10.1007/s00210-008-0341-4.CrossRefPubMedGoogle Scholar
  104. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology. 1996;46:388–93. https://www.ncbi.nlm.nih.gov/pubmed/8614500
  105. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain. 2000;123(Pt 11):2297–305. https://www.ncbi.nlm.nih.gov/pubmed/11050029CrossRefGoogle Scholar
  106. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251–3. https://www.ncbi.nlm.nih.gov/pubmed/14913646
  107. Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69:183–9.  https://doi.org/10.1002/syn.21805.CrossRefPubMedGoogle Scholar
  108. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or – dopaminergic malignant syndrome – due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9:175–8. https://www.ncbi.nlm.nih.gov/pubmed/12573874CrossRefGoogle Scholar
  109. St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson’s disease and other synucleinopathies. Mov Disord. 2017;32:645–58.  https://doi.org/10.1002/mds.27018.CrossRefPubMedGoogle Scholar
  110. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson’s disease. Brain. 2002;125:2058–66.  https://doi.org/10.1093/brain/awf214.CrossRefPubMedGoogle Scholar
  111. Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology. 2004;63:746–8.  https://doi.org/10.1212/01.wnl.0000134672.44217.f7.CrossRefPubMedGoogle Scholar
  112. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. 2005;62:905–10.  https://doi.org/10.1001/archneur.62.6.905.CrossRefPubMedGoogle Scholar
  113. Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients. Mov Disord. 2012;27:106–12.  https://doi.org/10.1002/mds.23954.CrossRefPubMedGoogle Scholar
  114. Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75:141–3. https://www.ncbi.nlm.nih.gov/pubmed/14707325
  115. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease. Neurology. 1998;50:1323–6. https://www.ncbi.nlm.nih.gov/pubmed/9595981CrossRefGoogle Scholar
  116. Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord. 2013;28:1064–71.  https://doi.org/10.1002/mds.25364.CrossRefPubMedGoogle Scholar
  117. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589–95.  https://doi.org/10.1001/archneurol.2010.65.CrossRefPubMedGoogle Scholar
  118. Weiss JL, Cohn CK, Chase TN. Reduction of catechol-O-methyl-transferases activity by chronic l-dopa therapy. Nature. 1971;234:218–9. https://www.ncbi.nlm.nih.gov/pubmed/4943087CrossRefGoogle Scholar
  119. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.  https://doi.org/10.1002/ana.10609.CrossRefGoogle Scholar
  120. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol. 2005;4:605–10.  https://doi.org/10.1016/S1474-4422(05)70146-0.CrossRefPubMedGoogle Scholar
  121. Woitalla D, Muller T, Benz S, Horowski R, Przuntek H. Transdermal lisuride delivery in the treatment of Parkinson’s disease. J Neural Transm Suppl. 2004;68:89–95. https://www.ncbi.nlm.nih.gov/pubmed/15354393
  122. Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect. 1993;91:181–95. https://www.ncbi.nlm.nih.gov/pubmed/8390270CrossRefGoogle Scholar
  123. Yu XX, Fernandez HH. Dopamine agonist withdrawal syndrome: a comprehensive review. J Neurol Sci. 2017;374:53–5.  https://doi.org/10.1016/j.jns.2016.12.070.CrossRefPubMedGoogle Scholar
  124. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46.  https://doi.org/10.1056/NEJMoa054830.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PharmacologyTeikyo University School of MedicineItabashi, TokyoJapan

Section editors and affiliations

  • Toshiharu Nagatsu
    • 1
    • 2
  • Akira Nakashima
    • 3
  1. 1.Fujita Health University School of MedicineToyoakeJapan
  2. 2.Institute of Environmental MedicineNagoya UniversityNagoyaJapan
  3. 3.Department of Physiological ChemistryFujita Health University School of MedicineToyoake, AichiJapan

Personalised recommendations

Cite entry